David Suhocki, PA
Medical · Wolcott, CTNPI 1861483414
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,000 of the $6,226 with a category attached, or 64.2%. AbbVie accounts for 83.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $4,497 and has fallen 84.3% since, to $707 in 2025. Among medical clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $52.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Johnson & Johnson$360
- Amgen$213
- E.r. Squibb & Sons, L.L.C.$146
- UCB, Inc.$114
- Lilly USA, LLC$48
- plus $139 from 5 others
What the payments were for
- Consulting fees$4,00064%
- Travel & lodging$441%
- Food & beverage$2,08333%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $5,206 |
| Johnson & Johnson | 17 | $360 |
| Amgen | 13 | $213 |
| E.r. Squibb & Sons, L.L.C. | 7 | $146 |
| UCB, Inc. | 3 | $114 |
| Lilly USA, LLC | 2 | $48 |
| Galderma Laboratories, L.p. | 2 | $43 |
| Novartis | 2 | $40 |
| Sanofi | 1 | $27 |
| Pfizer | 1 | $23 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$4,000
How this compares
$6,226 in reported general payments places this provider in the 90th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 33 | $131,524 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 199 | $7,612 |
| Ivermectin | 17 | $4,096 |
| Tacrolimus | 32 | $3,221 |
| Fluorouracil | 31 | $2,462 |
| Metronidazole | 32 | $2,330 |
| CiclopiroxCiclopirox Olamine | 101 | $1,826 |
| Triamcinolone Acetonide | 183 | $1,822 |
| Doxycycline Hyclate | 104 | $1,339 |
| Clobetasol Propionate | 37 | $924 |
| Mupirocin | 129 | $837 |
| Gentamicin Sulfate | 23 | $751 |
| Hydrocortisone | 64 | $718 |
| Imiquimod | 21 | $660 |
| Fluocinonide | 13 | $634 |
Paid to pharmacies, not to this prescriber.
Other medical in Wolcott
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Alyssa GreenleafSouthington$26K
- Mark VolpeSuffield$21K
- Josephine DiazSuffield$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.